Goldman Sachs Group Inc Aptinyx Inc. Transaction History

Goldman Sachs Group Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 May 14, 2024	BUY	$0.38 - $2.58 $4,689 - $31,842	12,342 New	12,342 $7,000
Q2 2022 Aug 15, 2022	SELL	$0.38 - $2.58 $14,175 - $96,246	-37,305 Reduced 75.14%	12,342 $7,000
Q1 2022 May 16, 2022	BUY	$2.27 - $3.62 $10,335 - $16,481	4,553 Added 10.1%	49,647 $112,000
Q4 2021 Feb 14, 2022	BUY	$2.11 - $3.0 $4,629 - $6,582	2,194 Added 5.11%	45,094 $121,000
Q3 2021 Nov 10, 2021	BUY	$2.21 - $2.89 $94,809 - $123,981	42,900 New	42,900 $100,000

Ticker APTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,715,696
Description
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

Stay updated on Goldman Sachs Group Inc with notifications on news.